Erasca Q3 net loss $30.6M, cash $362M; patent issued for pan-RAS drug ERAS-0015

Erasca, Inc.

2025-Q3 EPS reported -$0.34 vs consensus -$0.11 ▼ miss (-222.6%)

Net loss $30.6M ($0.11/sh) vs $31.2M in Q3 2024; R&D down to $22.5M from $27.6M.
Cash $362.4M as of Sep 30, 2025 (down from $440.5M Dec 31); runway into H2 2028.
U.S. composition of matter patent issued for ERAS-0015 covering composition through Sep 2043.
Promoted Robert Shoemaker, Ph.D., from SVP research to chief scientific officer.
Initial Phase 1 monotherapy data for ERAS-0015 and ERAS-4001 expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.